CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.

Pooled CRISPR screens can perturb every gene in the genome in a single experiment, generating millions of sequencing reads that have to be converted into a short list of genes that actually matter. AI ...

Since its breakthrough development more than a decade ago, CRISPR has revolutionized DNA editing across a broad range of fields. Now scientists are applying the technology's immense potential to human ...

A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a point-of-care testing (POCT) system based on microfluidic CRISPR-Dx technology, ...

CRISPR-based genome engineering revolutionized the gene-editing field by making experimental workflows considerably easier, faster, and more efficient than previous methods. Still, generating reliable ...

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit ...

CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading ...

CRISPR Therapeutics (NasdaqGM:CRSP) has come under pressure after a six day losing streak that cut the stock by about 18%, erasing roughly US$1.1b in market value and drawing attention to its ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...